StreetInsider.com News Articles

Form SCHEDULE 13G/A Tonix Pharmaceuticals Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260814/26925248.html

Form SCHEDULE 13G/A Tonix Pharmaceuticals Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260814/26925248.html

Form SCHEDULE 13G Tonix Pharmaceuticals Filed by: AQR CAPITAL MANAGEMENT LLC

Thu, 13 Aug 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26917653.html

Form SCHEDULE 13G Tonix Pharmaceuticals Filed by: AQR CAPITAL MANAGEMENT LLC

Thu, 13 Aug 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260813/26917653.html

Tonix Pharma (TNXP) PT Raised to $27 at Raymond James

Mon, 10 Aug 2026 13:46:07 -0400

Raymond James analyst Tiago Fauth raised the price target on Tonix Pharma (NASDAQ: TNXP) to $27.00 (from $26.00) while maintaining a Strong Buy rating.

The analyst comments "Thoughts on the quarter. In Tonmya’s second full quarter on the market, net sales nearly tripled q/q to $11M, well above the level we identified in our preview (link) as an encouraging signal that the launch was on track and recent payer-access gains were beginning to translate into stronger Rx monetization (albeit from a small base early in the launch). With management highlighting the potential for greater downstream pull-through from recent GPO agreements in

Tonix Pharma (TNXP) PT Raised to $27 at Raymond James

Mon, 10 Aug 2026 13:46:07 -0400

Raymond James analyst Tiago Fauth raised the price target on Tonix Pharma (NASDAQ: TNXP) to $27.00 (from $26.00) while maintaining a Strong Buy rating.

Form 10-Q Tonix Pharmaceuticals For: Jun 30

Mon, 10 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260810/26894834.html

Form 10-Q Tonix Pharmaceuticals For: Jun 30

Mon, 10 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260810/26894834.html

Form 8-K Tonix Pharmaceuticals For: Aug 10

Mon, 10 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26894269.html

Form 8-K Tonix Pharmaceuticals For: Aug 10

Mon, 10 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26894269.html

Tonix Pharma (TNXP) Tops Q2 EPS by 27c

Mon, 10 Aug 2026 07:02:16 -0400

Tonix Pharma (NASDAQ: TNXP) reported Q2 EPS of ($2.44), $0.27 better than the analyst estimate of ($2.71). Revenue for the quarter came in at $13.54 million versus the consensus estimate of $6.96 million.

For earnings history and earnings-related data on Tonix Pharma (TNXP) click here.

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Mon, 10 Aug 2026 07:00:00 -0400

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives)

First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD)

Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending final FDA review and agreement on study